Participated · Series D · Aug 2026

Abcuro develops immunotherapies intended to benefit people with debilitating and progressive rare autoimmune diseases by selectively targeting and depleting highly cytotoxic T cells. Its lead program, ulviprubart, is a monoclonal antibody that targets killer cell lectin like receptor G1 (KLRG1) and is currently being evaluated for the treatment of Inclusion Body Myositis (IBM). The company plans to use proceeds from the Series D to support a new potentially registrational clinical study of ulviprubart in patients with less severe IBM. Abcuro is led by CEO Alex Martin and is based in Newton, MA. Financially, it has just completed a $66M Series D financing led by New Leaf Venture Partners with participation from a broad syndicate of life sciences and strategic investors.

Participated · Series B · Jul 2026

Crystalys is advancing dotinurad, a next-generation, once-daily oral URAT1 inhibitor positioned as a second-line therapy to reduce uric acid, gout flares and tophi. Dotinurad was invented by Fuji Yakuhin and has regulatory approvals in Japan, China, the Philippines, Taiwan and Thailand, with supporting clinical data from those markets. The company is conducting the JEWEL clinical research program, which includes the Phase 3 RUBY and TOPAZ trials and the Phase 2 AMETHYST study to evaluate safety and efficacy across a broad spectrum of gout patients. Crystalys aims to position dotinurad as a best-in-class option for safety and efficacy and is preparing for global commercialization. The company is headquartered in San Diego and was co-founded by Catalys Pacific and Novo Holdings. With the announced $130 million Series B, Crystalys has increased its financial runway to support late-stage development and commercial readiness.

Participated · Series C · Apr 2026

Adcendo is advancing a pipeline of first- and potential best-in-class antibody-drug conjugates, integrating novel targets and optimized linker-payload combinations. The company is progressing three ADC programs: ADCE-T02 (Tissue Factor) in a Phase I Tiffany-01 cohort expansion across multiple solid tumors, ADCE-D01 (uPARAP) in Phase 1 dose escalation and expansion for soft tissue sarcoma and other mesenchymal cancers, and ADCE-B05 (undisclosed target) in preclinical evaluation and planned dose escalation in squamous cell carcinomas. Founded in 2017, Adcendo is headquartered in Copenhagen with operations in Boston, Massachusetts, and is led by a team with extensive ADC development and commercialization experience. The recent $75 million Series C financing is intended to fund the programs through upcoming clinical milestones and data readouts. No revenue or other operating metrics were disclosed in the provided articles.

Participated · Series A · Oct 2025

Adcytherix focuses on designing and developing highly selective antibody-drug conjugates that incorporate proprietary payloads aimed at improving efficacy, tolerability, and resistance profiles in oncology. Its lead candidate, ADCX-020, is progressing toward first-in-human studies, with IND and CTA filings targeted for the end of 2025. In parallel, the company is expanding a broader pipeline of differentiated ADCs that leverage its novel payload platform. Founded about 18 months ago and led by CEO and founder Jack Elands, the team draws on deep scientific and commercial expertise in the ADC field. The company positions itself as a European leader in next-generation ADC innovation, emphasizing precision targeting and payload differentiation. With the recent €105 million Series A financing, Adcytherix now has substantial resources to transition from preclinical research to clinical development. The new capital underpins both the advancement of ADCX-020 and the ongoing build-out of its proprietary ADC platform.

Participated · Series C · Oct 2025

Founded in 2014, Step Pharma is pioneering inhibition of cytidine triphosphate synthetase-1 (CTPS1) to create highly selective cancer therapies that spare healthy tissue. Its lead compound, dencatistat, is in a phase 1a dose-escalation study for solid tumours and is also being tested in a phase 1/2 trial for relapsed or refractory T- and B-cell lymphoma, an indication for which it holds FDA orphan-drug designation. A third clinical programme is underway in essential thrombocythaemia, and phase 1b expansion cohorts for CTPS2-null ovarian and endometrial cancers are slated to begin enrolling in 2026, with a lung-cancer cohort planned. CTPS2 loss occurs in roughly 15-20 % of these gynaecological tumours, creating a synthetic-lethal dependency on CTPS1 that dencatistat is designed to exploit. Proceeds from recent financing will also fund drug manufacture and pivotal toxicology ahead of phase 2 studies. Headquartered in Saint-Genis-Pouilly, France, the company is backed by investors such as Kurma Partners, V-Bio Ventures, Bpifrance, Pontifax, Hadean Ventures, Sunstone Life Science Ventures and others, and it closed a €38 million Series C round in October 2025.